Methods for the treatment of kidney fibrosis
The technology described herein is directed to the diagnosis, prognosis, and treatment of kidney fibrosis, e.g., chronic kidney disease.
1. A method of treatment for kidney fibrosis and/or chronic kidney disease comprising; measuring a level of expression of SPARC related modular calcium binding 2 (Smoc2) in a test sample obtained from a subject; treating the subject with a kidney fibrosis treatment when the expression level is increased relative to a reference level, wherein the kidney fibrosis treatment is selected from the group consisting of: dialysis; transplant; low protein diet; an ACE inhibitor; an angiotensin H receptor blacker (ARB); lipid control; D-vitamin supplementation; phosphate control; anemia control; acidosis prevention; and uric acid control.
2. The method of claim 1 , wherein the treatment comprises administering an antagonist or agonist of Smoc2.
3. The method of claim 1 , wherein the method further comprises measuring the level of expression of at least one gene selected from the group consisting of:
Cdh11; Gabrp; Mgp; Pld4; Mrc1; Syt12; Stra6; Scn7a; Sema3d; Pdpn; and Pltp.
4. The method of claim 1 , wherein the method further comprises measuring the level of expression of at least one gene selected from the group consisting of:
Cdh11; Gabrp; Mgp; Pld4; Mrc1; Syt12; Stra6; Scn7a; and Pltp.
5. The method of claim 1 , wherein the method further comprises measuring the level of expression of at least one gene selected from the group consisting of:
Cdh11; Mrc1; Pltp; and MGP.
6. The method of claim 1 , wherein the method further comprises measuring the level of expression of at least one gene selected from the group consisting of:
Cdh11; Pltp; and MGP.
7. The method of claim 1 , wherein the expression level of Smoc2 is determined by measuring the level of a nucleic acid.
8. The method of claim 1 , wherein the expression level of Smoc2 is measured by measuring the level of the polypeptide expression product.
9. The method of claim 1 further comprising depleting the sample of abundant proteins prior to the measuring step.
10. The method of claim 9 , wherein the depletion step comprises affinity chromatography.
11. The method of claim 1 , wherein the test sample is a urine sample.
12. The method of claim 1 , wherein the reference level is the expression level in a prior sample obtained from the subject.
13. The method of claim 1 , wherein the kidney fibrosis is chronic progressive fibrosis.
14. The method of claim 1 , wherein the subject is a subject with a condition selected from the group consisting of:
diabetes; diabetic nephropathy; hypertension; acute kidney injury; chronic kidney disease; an autoimmune disease; systemic lupus erythematosus; renal transplant rejection; renal or systemic infections, streptococcal infections, bacterial endocarditis, human immunodeficiency virus, hepatitis B, C; and inflammatory or infiltrative disease; membranoproliferative glomerulonephritis; IgA nephropathy; chemical toxicity poisoning; mechanical damage affecting the kidneys; renal ischemia; microangiopathies; renal artery occlusion; renal atheroembolism; renal vein thrombosis; obstruction of the urinary tract; nephrolithiasis; primary genetic alterations; polycystic kidney disease; and idiopathic chronic kidney disease.
15. A kit for performing the method of claim 1 .
16. A method of treating kidney fibrosis or chronic kidney disease, the method comprising administering an antagonist or agonist of SPARC related modular calcium binding 2 (Smoc2).
17. A method of treatment for kidney fibrosis and/or chronic kidney disease comprising;
treating a subject with a kidney fibrosis treatment when the subject has been determined to have an increased expression level of SPARC related modular calcium binding 2 (Smoc2) relative to a reference level.
18. A method of treatment for kidney fibrosis and/or chronic kidney disease comprising;
measuring a level of expression of SPARC related modular calcium binding 2 (Smoc2) in a test sample obtained from a subject; and
treating the subject with a Smoc2 antagonist selected from an antibody reagent and an antibody when the expression level is increased relative to a reference level.